Mini-Networking Night: Medical Science Liaison & Medical Affairs
Date - 02/12/2020
6:00 pm - 7:35 pm
Mini-Networking Night: Medical Science Liaison & Medical Affairs
Mini-Networking Night focused on careers in medical science liaison and medical affairs will feature guests from Merck Canada, Baylis Medical Company, Novo Nordisk, AstraZeneca, and Eisai Canada on December 2nd, 2020. Interested in learning more about this career path, join us for an exciting networking night where some of the most prominent leaders in the field will talk about their path to success!
Special note: Thank you for your interest in our mini-networking event. We understand that the ITCS information session is running concurrently with the mini-networking event. In order to mitigate this, the ITCS session will be recorded and an exclusive recording of the information session is available to those interested. Thank you for your understanding!
Date: Wednesday, December 2nd, 2020
Registration: Registration for all students, post-docs and other research trainees at the University of Toronto or the affiliated research institutions will open on Monday, November 16th. Registration for non-members will open on Tuesday, November 17th, 2020.
Time: 6:00 – 7:35 pm (Toronto, ON local time; GMT-5)
Location: online through Zoom. The Zoom link will be sent to those registered.
Very limited space available. Registered individuals who do not show up will be prevented from registering for future events.
Guests for this event:
Nathan Schachter, PhD – Medical Science Liaison – Merck Canada
Moien Giashi, PhD – Scientific Affairs Associate – Baylis Medical Company
Kangbin Zhou, PhD – Medical Science Liaison – Novo Nordisk
Fabian Yu, PhD – Medical Science Liaison – AstraZeneca
Shakira Hakimzadah, PharmD – Medical Science Liaison – Eisai Canada
Nathan Schachter, PhD
Nathan completed his PhD at the University of Toronto where he studied the genetic basis of breast cancer development in mice. As a post-doctoral fellow at Sickkids, he then researched the role of large DNA deletions in cancer. Next, as a Research Associate at the University Health Network, he helped launch a pan-Canadian liquid biopsy trial that enrolled patients with inherited cancer predispositions. Most recently, in March of 2019, Nathan joined Merck Canada as a Medical Science Liaison in Oncology.
Moien Giashi, PhD
Moien is a Scientific Affairs Associate at Baylis Medical Company where he works with various functions such as IP, R&D and Marketing. Prior to that Moien was a Venture Manager at Creative Destruction Lab at Rotman School of Management supporting various startups. The startups that Moien managed raised a cumulative amount of $12M from various investors.
Moien is a Chemical Engineer by training and has done his PhD in the Chemistry Department at the University of Toronto where his research was mostly focused on Bioprinting, Microfluidics and Polymer Synthesis. During his PhD Moien was heavily involved with various management consulting groups on campus; he was a consultant and team lead with UCG (University Consulting Group) and he was an executive member of the Graduate Management Consulting Association (GMCA).
Kangbin Zhou, PhD
Kangbin has been a specialty Medical Science Liaison at Novo Nordisk since January 2019. He is specialized on 4 therapeutic areas including cardiology, obesity, chronic kidney disease (CKD), and non-fatty liver steatohepatitis (NASH) and covers the entire western Canada (from BC to Manitoba). He describes his role as a medical scientific 007: he works in the field to educate healthcare professionals (HCPs) with the latest clinical data and develop key opinion leaders into speakers and medical experts, to support sales representatives for their interactions with HCPs, to provide support to physicians who are principal investigators on clinical trials. Working closely with physicians from 4 special areas, particularly cardiologists, general internists, nephrologists and gastroenterologists, he jokes about being “a jack of all trades and master of none” as he constantly needs to upgrade his knowledge in all these therapeutic areas.
Before joining Novo Nordisk, he worked in a variety of part gigs including being a biomedical content consultant for Meta (under the umbrella of Chan Zuckerberg Initiative), a contract medical writer for Integrated MedHealth Communication, and briefly a data analyst for Knowtions (a start-up AI company) during his last year of his PhD program. He completed a PhD degree at the Department of Pharmacology & Toxicology at University of Toronto (U of T) with a specialization in clinical cardiovascular pharmacology. In his spare time, he is raising a golden retriever and is an amateur salsa and hip-hop dancer who frequents social dance scenes and occasionally performs on stage with his dance friends in Vancouver. During his PhD, he founded the first open-style dance club at U of T and hosted the first tri-campus dance competition in 2016 which garnered him the Romet Award and an interview with U of T Magazine. Dance is his passion and his dream is to open a dance studio before the age of 40.
Fabian Yu, PhD
Fabian received his PhD through the Institute of Medical Science Program. His doctoral research was focused on the lysosomal storage disorders and gene therapy. During the early period of his PhD, Fabian had the opportunity to do an internship at genomics start-up called GeneYouIn and also work as a Junior Associate for Roche Diagnostics. Later Fabian relocated along with his lab to the Medical College of Wisconsin. During this time, Fabian was selected to participate in a technology transfer internship at the Blood Research Institute. Additionally, he also volunteered as a Consultant for local biotechnology startups and also served as the local project lead for the Ximbassador program for Ximbio. At the end of his PhD Fabian was recruited into a pilot Specialty Medicine Rotational program at Bayer. In this role he had exposure to Medical Affairs, Commercial Operations, and Patient Access. Fabian later transitioned to a Medical Science Liaison role covering Bayer’s prostate cancer portfolio, and most recently Fabian has moved over to AstraZeneca where he is currently a Medical Science Liaison covering the lung cancer portfolio.
Shakira Hakimzadah, PharmD
Shakira Hakimzadah is a Medical Science Liaison and Registered Pharmacist graduated from the University of Toronto. She has experience in hospital pharmacy, community pharmacy and the pharmaceutical industry spanning neurology, nephrology, and oncology. In her primary role as a Medical Science Liaison, Shakira focuses on building connections and maintaining relationships with clinicians, researchers, and healthcare practitioners to optimize outcomes for patients via scientific and clinical exchange.
***All students, post-docs and other research trainees at the University of Toronto or the affiliated research institutions must register with their institutional email address to take advantage of the early registration .***
This event is fully booked.